Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial. (PubMed, Open Forum Infect Dis) - Sep 18, 2026 - "In Part B, the median time to healing was 19.0 days, with a 63% healing rate. Pritelivir demonstrated encouraging efficacy and favorable safety in immunocompromised adults with limited treatment options, supporting Phase 3 evaluation for the treatment of refractory HSV infection in this population."
Clinical • Journal • P2 data • Herpes Simplex • Infectious Disease
|
|
Aaron Dane; Alexander Birkmann; Anna Wald; Bernadette Surujbally; Burkhard Timmler; Camille N Kotton; Genofeva A Papanicolaou; Hollis R O'Neal; Joerg Albrecht; Joshua T Schiffer; Kimberly A Workowski; Manickam Rangaraju; Mayur Ramesh; Melanie E Sumner; Michael G Ison; Moti Ramgopal; Nicolas C Issa; Pranatharthi Chandrasekar; Princy N Kumar; Robin K Avery; Roy F Chemaly; Tanya S Schreibman
|